Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2020 Earnings Results

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 1.27%

The earnings report indicates that Arrowhead Pharmaceuticals faced challenges in the third quarter, particularly with its EPS performance. The stock reacted negatively, dropping 1.27%, likely due to the significant miss on EPS expectations. Investors may be cautious as the company did not provide revenue figures or future guidance, leaving uncertainty about its financial outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.13	N/A	-78.08%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about the current financial environment. They noted that the lack of revenue guidance reflects ongoing uncertainties.

Management did not provide specific revenue figures for the quarter.

The company acknowledged challenges in meeting earnings expectations.

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 1.27%

Key numbers

Management commentary

Arrowhead Pharmaceuticals, Inc.

More earnings this week

Arrowhead Pharmaceuticals Misses on EPS, Stock Down 1.27%

Key numbers

Management commentary